Ablynx receives GLP certification at Ghent plant

Published: 28-Jul-2011
Research & Development

Now able to carry out pre-clinical analytical testing and pharmacokinetics in-house


Ablynx, a Belgian developer of nanobodies, has received a Certificate of Good Laboratory Practise (GLP) from the Belgian Scientific Institute of Public Health (IPH) for its new GLP unit established in Ghent, Belgium.

The granting of the certificate follows an inspection conducted by the Belgian authorities in May.

With this certification, Ablynx is now able to carry out pre-clinical analytical testing and pharmacokinetics studies in-house, to the required regulatory standard.

Dr Edwin Moses, ceo and chairman of Ablynx, said being awarded the certificate confirms the company’s commitment to high quality standards.

‘With this certificate, we no longer solely rely on third parties to carry out the pre-clinical GLP testing for our programmes,’ he said. ‘This enables us to retain more control on quality, timing and associated costs.’

See more

You may also like

Research & Development

Sanofi to acquire Ablynx for €3.9 billion

Read more
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Sanofi to acquire Ablynx for €3.9 billion

The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Research & Development

Novel Nanobody to begin clinical development in osteoarthritis

Ablynx to receive €15m milestone payment from Merck
Ingredients

Ablynx acheives first milestone as part of collaboration with Novo Nordisk

Multi-specific nanobody candidate reaches discovery milestone
Regulatory

Ablynx to receive an €8m milestone payment as Boehringer Ingelheim starts a Phase I study with an anti-CX3CR1 nanobody

The anti-CX3CR1 nanobody was discovered and developed as part of a longstanding strategic alliance between both parties
Research & Development

Ablynx to work with Novo Nordisk on nanobody drug discovery

Will receive a €5m upfront payment, research funding and potential future milestones and royalties on net sales
Research & Development

Ablynx enters €13m immuno-oncology collaboration expansion with Merck

Takes responsibility for the discovery and development of up to 12 additional Nanobody programmes
Research & Development

Ablynx and Taisho Pharmaceutical enter agreement to develop rheumatoid arthritis drug in Japan

Ablynx will receive an upfront payment of US$3m
Subscribe now